Fosfomycin-Daptomycin and Other Fosfomycin Combinations as Alternative Therapies in Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus | Zendy

Carmen Garrigós | Zendy; Óscar Murillo | Zendy; Jaime Lora-Tamayo | Zendy; R. Verdaguer | Zendy; Fé Tubau | Zendy; Carmen Cabellos | Zendy; Javier Cabo | Zendy; Javier Ariza | Zendy

Open Access

Fosfomycin-Daptomycin and Other Fosfomycin Combinations as Alternative Therapies in Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus

Author(s) -

Carmen Garrigós,

Óscar Murillo,

Jaime Lora-Tamayo,

R. Verdaguer,

Fé Tubau,

Carmen Cabellos,

Javier Cabo,

Javier Ariza

Publication year - 2012

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01570-12

Subject(s) - fosfomycin , daptomycin , imipenem , staphylococcus aureus , microbiology and biotechnology , medicine , antibiotics , methicillin resistant staphylococcus aureus , antibacterial agent , vancomycin , biology , antibiotic resistance , bacteria , genetics

The efficacy of daptomycin, imipenem, or rifampin with fosfomycin was evaluated and compared with that of daptomycin-rifampin in a tissue cage model infection caused by methicillin-resistant Staphylococcus aureus (MRSA). Strain HUSA 304 was used. The study yielded the following results for MICs (in μg/ml): fosfomycin, 4; daptomycin, 1; imipenem, 0.25; and rifampin, 0.03. The study yielded the following results for minimum bactericidal concentration (MBC) (in μg/ml): fosfomycin, 8; daptomycin, 4; imipenem, 32; and rifampin, 0.5. Daptomycin-rifampin was confirmed as the most effective therapy against MRSA foreign-body infections. Fosfomycin combinations with high doses of daptomycin and rifampin were efficacious alternative therapies in this setting. Fosfomycin-imipenem was relatively ineffective and did not protect against resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research